Evidence brief
GHK-Cu
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
No FDA-approved injectable GHK-Cu drug product.
A three-amino-acid copper complex with topical and laboratory research. That research does not validate injectable, whole-body, or longevity claims.
- How strong is the evidence?
- Emerging
Some studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation. - What evidence exists?
- Preclinical or formulation evidence
The research used cells, animals, or product-form tests. It does not establish benefit or safety in people. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as copper tripeptide-1 · glycyl-L-histidyl-L-lysine copper · GHK copper
Part of Healing and recovery peptides
Words used here
- preclinical
- research in cells, tissues, or animals before or outside testing in people
- formulation
- the ingredients and physical form of the finished product
- peptide
- a short chain of amino acids
- randomized
- assigned to study groups by chance
- route
- how the product enters the body
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- outcome
- what the study measured
- amino acid
- a small building block that makes peptides and proteins
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Small formulation-specific human studies exist, but broad regenerative and anti-aging outcomes are not established.
Copper binding and cell-level signaling are biologically plausible but not equivalent to clinical benefit.
Human information is limited, and FDA identifies injectable immunogenicity and impurity concerns.
Formulation and route strongly affect what evidence can be transferred.
02 · Identity
What it is
GHK-Cu is a copper complex of a three-amino-acid peptide. Cosmetic ingredients, topical study products, and compounded injections are different evidence categories.
Scientific group: Copper-binding tripeptide complex. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
None identified in the United States.
- No FDA-approved drug indication
04 · Research results
What the research shows
One small randomized topical study after laser resurfacing had 13 people who completed it. It found no significant between-group improvement in erythema, wrinkles, or objectively assessed skin quality, although questionnaire-reported satisfaction was higher in the GHK-Cu group. FDA says human data are limited and flags potential immunogenicity from aggregates and peptide-related impurities for injectable routes.
The evidence does not establish that injected GHK-Cu rejuvenates organs, repairs injury throughout the body, reverses aging, or produces the same effects as a studied topical formulation.
Exact product
A topical product and an injectable product are not the same evidence question. Topical formulations, compounded non-injectable products, and injectable products are different evidence questions. FDA separately flags injectable GHK-Cu risks.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“GHK-Cu has been studied in people.”
Yes, but the cited topical trial had 13 completers, found no significant objective improvement in erythema, wrinkles, or skin quality, and reported higher patient satisfaction. It does not establish broader outcomes or other routes.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- A specific topical copper-tripeptide formulation after CO2 laser resurfacing. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Topical GHK-Cu evidence proves injectable GHK-Cu works systemically.”
Route, formulation, exposure, product quality, and endpoint differ. Evidence cannot be transferred by ingredient name alone.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Topical study formulations versus compounded injectable products. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Injectable GHK-Cu is proven safe.”
FDA identifies limited human data and potential immunogenicity related to aggregation and peptide impurities.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Compounded injectable GHK-Cu. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about GHK-Cu
No FDA-approved injectable GHK-Cu drug product. No approved product is identified in the United States.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
One small randomized topical study after laser resurfacing had 13 people who completed it. It found no significant between-group improvement in erythema, wrinkles, or objectively assessed skin quality, although questionnaire-reported satisfaction was higher in the GHK-Cu group. FDA says human data are limited and flags potential immunogenicity from aggregates and peptide-related impurities for injectable routes.
The evidence does not establish that injected GHK-Cu rejuvenates organs, repairs injury throughout the body, reverses aging, or produces the same effects as a studied topical formulation.
07 · Safety
Safety limits for this record
Route and formulation are part of the claim. This guide does not provide injectable-use, compounding, cosmetic-treatment, or wound-care instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief separates topical formulation studies from injectable-product claims.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.